Glaukos Corporation delivered its Q2 earnings on July 29, and the immediate market response frames this week's most interesting tension: a stock up 35% year-to-date, carrying 8% short interest and a fresh UBS downgrade, yet still defended by a chorus of Buy-rated analysts lifting targets.
The positioning story is less threatening than the short interest headline suggests. At 8.1% of the free float — up 53% over the past month — the bears have clearly been building. But the borrow market tells a different story. Availability runs at roughly 1,200% of outstanding short interest, meaning there are around 12 shares sitting in the lending pool for every one already borrowed. Cost to borrow is a negligible 0.48%, barely changed from a month ago. There is no squeeze pressure here, and no signal that the short build is being driven by a tight or costly borrow. The ORTEX short score of 49.3 sits near the midpoint, suggesting the overall short setup is unremarkable despite the elevated SI level. Options positioning adds one genuinely interesting data point: the put/call ratio collapsed to 3.17 on July 28, versus a 20-day mean of 10.2 — almost 1.6 standard deviations below recent norms. After weeks of heavily put-skewed positioning, call volume surged on earnings day. That's a notable reversal, consistent with investors buying upside exposure into the print rather than hedging downside.
The Street is divided in a specific way. The majority of recent analyst action has been constructive. Truist raised its target to $180, Stifel lifted to $175, Citigroup to $175, and HC Wainwright initiated with a Buy at $168 — all within the past four weeks. Against that backdrop, UBS's same-day initiation at Neutral with a $150 target lands as a deliberate contrast. The $150 target sits fractionally below the current price of $151.33, making it the most cautious mark on the board. The bull case centres on iDose TR adoption and the Epioxa pipeline; the bear case focuses on LCD reimbursement restrictions and a slow prior-authorisation process that could cap near-term penetration. With the consensus rating sitting at hold and the mean target around $164, the Street is broadly constructive but clearly not unanimous. Valuation remains stretched — the EV/EBITDA multiple is above 375x, though it has compressed sharply over the past month as the stock pulled back from recent highs.
Insider activity reinforces the cautious-but-not-alarmed read. The CFO, Alex Thurman, sold 30,000 shares across three transactions between July 1 and July 16 — $4.65m in total proceeds at prices between $150 and $160. CEO Thomas Burns sold just over 4,000 shares at $142.57 in late June. All told, the 90-day net insider position shows roughly 79,000 net shares sold, worth around $11.6m. None of these trades carry high significance scores, and the pattern looks more like systematic selling into strength than a coordinated exit. Still, insiders have been consistent sellers across the entire recent rally, with no buying to provide a counterweight.
The one prior earnings data point in the record — May's Q1 print — saw the stock fall 5.9% the day after results before recovering 10.7% over the following five sessions. That pattern, a sharp initial drop followed by a meaningful rebound, is worth noting as the market digests this week's Q2 numbers. Peers moved broadly higher on the day: BVS gained 6.1%, STE added 5.5%, and MDT rose 3.2%, while GKOS slipped 0.4%. That modest underperformance against a rising medtech tape, on the day of its own earnings release, is the detail worth tracking as the week closes.
See the live data behind this article on ORTEX.
Open GKOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
